- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Rank correlation.
Displaying page 1 of 1.
EudraCT Number: 2013-001662-42 | Sponsor Protocol Number: 20120249 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) IT (Completed) GB (Completed) GR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004785-18 | Sponsor Protocol Number: PKBoxing-1 | Start Date*: 2014-11-18 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: PET imaging of neuroinflammatory consequences of chronic repetitive head injury in Muay Thai boxing | ||
Medical condition: n/a | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003638-28 | Sponsor Protocol Number: 2015/576 | Start Date*: 2015-09-30 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of disconti... | ||||||||||||||||||
Medical condition: Rheumatoid arthritis and osteoporosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001755-72 | Sponsor Protocol Number: GBG88 | Start Date*: 2016-11-22 | |||||||||||
Sponsor Name:German Breast Group | |||||||||||||
Full Title: Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (Ge... | |||||||||||||
Medical condition: Patients with early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005017-31 | Sponsor Protocol Number: DERN | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | |||||||||||||
Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY | |||||||||||||
Medical condition: advanced or metastatic Nose Pharynx Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004137-21 | Sponsor Protocol Number: 78591.041.21 | Start Date*: 2021-10-28 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study | ||
Medical condition: respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000266-11 | Sponsor Protocol Number: 2012-772 | Start Date*: 2014-05-27 |
Sponsor Name:HOSPICES CIVILS DE LYON | ||
Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer. | ||
Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery. | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004407-39 | Sponsor Protocol Number: IB1001-203 | Start Date*: 2019-09-18 |
Sponsor Name:IntraBio Ltd. | ||
Full Title: Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study. | ||
Medical condition: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003184-62 | Sponsor Protocol Number: J1369 | Start Date*: 2014-04-23 | |||||||||||
Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |||||||||||||
Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer... | |||||||||||||
Medical condition: Previously treated metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002385-23 | Sponsor Protocol Number: AFT-MXCF-03 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:AFT Pharmaceuticals Ltd | |||||||||||||
Full Title: A phase 3 randomised, double blind, multiple dose, parallel group efficacy study of different doses of phenylephrine hydrochloride combined with paracetamol and/or ibuprofen in participants with na... | |||||||||||||
Medical condition: nasal congestion | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011299-32 | Sponsor Protocol Number: 20060359 | Start Date*: 2010-08-06 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence | |||||||||||||
Medical condition: Early-stage non-metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) LV (Completed) FR (Completed) BE (Completed) SK (Completed) NL (Completed) IE (Prematurely Ended) DK (Completed) SI (Completed) GR (Completed) IT (Completed) BG (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005049-11 | Sponsor Protocol Number: AAA-III-01 | Start Date*: 2012-04-25 | ||||||||||||||||
Sponsor Name:Advanced Accelerator Applications | ||||||||||||||||||
Full Title: A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperabl... | ||||||||||||||||||
Medical condition: Patients with inoperable, progressive, OctreoScan® positive, well-differentiated neuroendocrine tumours of the small bowel (midgut carcinoid tumours), who are treated with 20 mg or 30 mg Octreotide... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) PT (Completed) FR (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000382-16 | Sponsor Protocol Number: 1063-Dara-H-VERUMM | Start Date*: 2021-04-07 | |||||||||||
Sponsor Name:Medical Center - University of Freiburg | |||||||||||||
Full Title: Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination with bortezomib-dexamethasone ... | |||||||||||||
Medical condition: Relapsed and refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
